Sentences with phrase «changes in the share price»

All returns include changes in share price, and reinvestment of any dividends and capital gains distributions.

This means in the example above, your investment is simply mirroring the changes in the share price of Company X — at no time do you own any shares or have the option of owning any shares from your Binary Option.

The Services / Technology table presents 10 of the leading mining services and technology companies on the ASX, listing the latest market cap, and one - day, one - week and one - year percentage change in share prices.

The Services / Technology table presents 10 of the world's leading mining services and technology companies, listing the latest market cap, and one - day, one - week and one - year percentage change in share prices.

Total return includes change in share prices and, in each case, includes reinvestment of dividends and capital gain distributions.

Among them is the sequence of time intervals on a stock exchange when there is a change in share prices, which does not happen uniformly.

This is the signal from the 20 - day MA which is used to monitor changes in share price.

Equities risk: includes the risk that changes in share prices will negatively impact on the value of investment.

The performance figures presented reflect the total return performance for Institutional Class shares (after fees) and reflect changes in share price and reinvestment of dividend and capital gain distributions.

I hope all your buys work out well for you, but as you say its not the change in share prices that are the reason for our choices, but the continuous increase in the dividend payments.

He approves of activists who are «looking for permanent changes in the business for the better» but disapproves of activists «looking for a specific change in the share price of the business.»

Therefore, the Fund is most suitable for long - term investors who are willing to hold their shares for extended periods of time through market fluctuations and the accompanying changes in share prices.

In that case, a 1 % change in the share price can turn into a $ 1,000 loss (which is 20 % of your investment).

While PSTG - US «s change in share price of -25.99 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of 6.27 % is above the peer median.

While RDI - US «s change in share price of 21.29 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of -1.45 % is below peer median.

While OSIS - US «s change in share price of 31.13 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of 7.80 % is above the peer median.

PDCO - US «s change in share price of 1.13 % for the last 12 months is better than its peer median.

While GRMN - US «s change in share price of 16.70 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of 0.87 % is below peer median.

ASB - US «s change in share price of 39.13 % for the last 12 months is better than its peer median.

While CTS - US «s change in share price of 27.12 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of -0.68 % is below peer median.

While DIOD - US «s change in share price of 26.51 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of 1.34 % is above the peer median.

While IBKC - US «s change in share price of 27.94 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of 0.57 % is above the peer median.

EVR - US «s change in share price of 45.36 % for the last 12 months is better than its peer median.

While GBCI - US «s change in share price of 32.74 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of 5.89 % is above the peer median.

KKR - US «s change in share price of 30.34 % for the last 12 months is better than its peer median.

However, changes in the share price and balance can affect future payouts.

As equity funds invest in stocks, any change in share prices will have a corresponding impact on the Net Asset Value (NAV) of the fund.

While ARES - US «s change in share price of 27.76 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of 7.95 % is above the peer median.

Average annual total returns include the change in share price and reinvestment of dividends and capital gain distributions.

Average annual total returns shown include the change in share price and reinvestment of dividends and capital gain distributions.

ii) Do you own too many stocks that actually experience radical changes in their share price and intrinsic valuation, often overnight?

SYBT - US «s change in share price of 61.61 % for the last 12 months is better than its peer median.

(10) Total return was calculated by dividing the net change in the share price, during the year, plus the dividends paid per share, during the year, by the closing share price on December 31 or the last trading day of the preceding year

While NBTB - US «s change in share price of 40.21 % for the last 12 months is in line with its peer median, its more recent 30 - day share price performance of 4.87 % is below peer median.

However, when I compare the change in share price of a leveraged ETF vs the non-leveraged version of that same ETF I see large differences in increase of share price that favors the leverage ETF.

Total Returns include change in share price, assume reinvestment of all distributions, and reflect the deduction of fund expenses and applicable fees.

Take their barometric reading: Fenwick & West's Venture Capital Barometer — the measurement of change in share price of Silicon Valley companies funded during the quarter compared with their previous financing round — was up 64 percent.

As an expert tribunal, the Commission merely applies its expertise to the evidence before it to explain why a lack of change in share price was not determinative of a material change issue.

Not exact matches

In the opinion of the Company's management, adjusted book value per share is useful in an analysis of a property casualty company's book value per share as it removes the effect of changing prices on invested assets (i.e., net unrealized investment gains (losses), net of tax), which do not have an equivalent impact on unpaid claims and claim adjustment expense reserveIn the opinion of the Company's management, adjusted book value per share is useful in an analysis of a property casualty company's book value per share as it removes the effect of changing prices on invested assets (i.e., net unrealized investment gains (losses), net of tax), which do not have an equivalent impact on unpaid claims and claim adjustment expense reservein an analysis of a property casualty company's book value per share as it removes the effect of changing prices on invested assets (i.e., net unrealized investment gains (losses), net of tax), which do not have an equivalent impact on unpaid claims and claim adjustment expense reserves.

The share prices of big entertainment companies have been extremely volatile over the past year as investors try to assess the winners and losers in the changing video ecosystem.

When you purchase a broad swath of equities, say an S&P 500 index fund, the returns you can expect over the next decade or so comprise four building blocks: the starting dividend yield, projected growth in real earnings per share, expected inflation, and the expected change in «valuation» — that is, the expansion or contraction in the price / earnings (P / E) multiple.

CHICAGO, May 2 - Kraft Heinz Co's quarterly profit beat expectations as the Tater Tots - maker benefited from tax changes in the United States and raised prices to counter higher input costs, sending shares up 4 percent after the bell.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

These risks and uncertainties include competition and other economic conditions including fragmentation of the media landscape and competition from other media alternatives; changes in advertising demand, circulation levels and audience shares; the Company's ability to develop and grow its online businesses; the Company's reliance on revenue from printing and distributing third - party publications; changes in newsprint prices; macroeconomic trends and conditions; the Company's ability to adapt to technological changes; the Company's ability to realize benefits or synergies from acquisitions or divestitures or to operate its businesses effectively following acquisitions or divestitures; the Company's success in implementing expense mitigation efforts; the Company's reliance on third - party vendors for various services; adverse results from litigation, governmental investigations or tax - related proceedings or audits; the Company's ability to attract and retain employees; the Company's ability to satisfy pension and other postretirement employee benefit obligations; changes in accounting standards; the effect of labor strikes, lockouts and labor negotiations; regulatory and judicial rulings; the Company's indebtedness and ability to comply with debt covenants applicable to its debt facilities; the Company's ability to satisfy future capital and liquidity requirements; the Company's ability to access the credit and capital markets at the times and in the amounts needed and on acceptable terms; and other events beyond the Company's control that may result in unexpected adverse operating results.

For purposes of the offering in Canada, if all of the shares have not been sold, after the Canadian underwriters have made a reasonable effort to sell the shares at the public offer price, the Canadian underwriters may from time to time decrease or change the offering price and the other selling terms provided that the price for the shares shall not exceed the public offer price and further provided that the compensation that is realized by the Canadian underwriters will be decreased by the amount that the aggregate price paid by the purchasers for the shares is less than the gross proceeds paid by the Canadian underwriters to us or the selling stockholders.

Even though the announcement indicated that this change in direction had yet to be reflected in any real actions other than a discussion by the company board of directors, NextGen's share price jumped 22 %.

Wadiak's changing role comes after a painful IPO for the meal kit delivery service, which first had to reduce its original IPO price and has since seen a significant drop in its share price.

Technical analysis is the study of trends in stock price changes and in trading volume, which is the number of shares traded in a day or month.

These included overly optimistic economic growth and oil price assumptions; cutting the contingency reserve by two - thirds; selling shares in GM at fire sale prices; raiding EI revenues; and even booking «savings» from unilateral changes to federal employees» sick leave benefits.